Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
Endovascular aortic repair with sac embolization for the prevention of type II endoleaks (the EVAR-SE study): study protocol for a randomized controlled multicentre study in Germany.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- معلومة اضافية
- المصدر:
Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE
- بيانات النشر:
Original Publication: [London] : BioMed Central, 2006-
- الموضوع:
- نبذة مختصرة :
Background: Beyond a certain threshold diameter, abdominal aortic aneurysms (AAA) are to be treated by open surgical or endovascular aortic aneurysm repair (EVAR). In a quarter of patients who undergo EVAR, inversion of blood flow in the inferior mesenteric artery or lumbar arteries may lead to type II endoleak (T2EL), which is associated with complications (e.g. AAA growth, secondary type I endoleak, rupture). As secondary interventions to treat T2EL often fail and may be highly invasive, prevention of T2EL is desirable. The present study aims to assess the efficacy of sac embolization (SE) with metal coils during EVAR to prevent T2EL in patients at high risk.
Methods: Over a 24-month recruitment period, a total of 100 patients undergoing EVAR in four vascular centres (i.e. Klinikum rechts der Isar of the Technical University of Munich, University Hospital Augsburg, University Hospital Dresden, St. Joseph's Hospital Wiesbaden) are to be included in the present study. Patients at high risk for T2EL (i.e. ≥ 5 efferent vessels covered by endograft or aneurysmal thrombus volume <40%) are randomized to one group receiving standard EVAR and another group receiving EVAR with SE. Follow-up assessments postoperatively, after 30 days, and 6 months involve contrast-enhanced ultrasound scans (CEUS) and after 12 months an additional computed tomography angiography (CTA) scan. The presence of T2EL detected by CEUS or CTA after 12 months is the primary endpoint. Secondary endpoints comprise quality of life (quantified by the SF-36 questionnaire), reintervention rate, occurrence of type I/III endoleak, aortic rupture, death, alteration of aneurysm volume, or diameter. Standardized evaluation of CTA scans happens through a core lab. The study will be terminated after the final follow-up visit of the ultimate patient.
Discussion: Although preexisting studies repeatedly indicated a beneficial effect of SE on T2EL rates after EVAR, patient relevant outcomes have not been assessed until now. The present study is the first randomized controlled multicentre study to assess the impact of SE on quality of life. Further unique features include employment of easily assessable high-risk criteria, a contemporary follow-up protocol, and approval to use any commercially available coil material. Overcoming limitations of previous studies might help SE to be implemented in daily practice and to enhance patient safety.
Trial Registration: ClinicalTrials.gov NCT05665101. Registered on 23 December 2022.
(© 2023. The Author(s).)
- References:
J Cardiovasc Surg (Torino). 2018 Feb;59(1):79-86. (PMID: 26221867)
Ann Vasc Surg. 2017 Oct;44:119-127. (PMID: 28479464)
Eur J Vasc Endovasc Surg. 2018 Dec;56(6):794-807. (PMID: 30104089)
J Endovasc Ther. 2018 Aug;25(4):418-425. (PMID: 29896999)
J Vasc Surg. 2016 Apr;63(4):895-901. (PMID: 26796291)
Surgeon. 2022 Jun;20(3):142-150. (PMID: 33958298)
J Vasc Surg. 2020 Feb;71(2):457-469.e1. (PMID: 31405762)
JAMA. 2013 Nov 27;310(20):2191-4. (PMID: 24141714)
J Endovasc Ther. 2010 Aug;17(4):517-24. (PMID: 20681769)
Br J Surg. 2018 Jan;105(1):68-74. (PMID: 29265406)
PLoS One. 2017 Feb 9;12(2):e0170600. (PMID: 28182753)
J Cardiovasc Surg (Torino). 2015 Dec;56(6):889-98. (PMID: 26372021)
J Endovasc Ther. 2020 Feb;27(1):109-116. (PMID: 31566053)
Eur J Vasc Endovasc Surg. 2011 Feb;41(2):186-92. (PMID: 21095141)
J Vasc Surg. 2019 Jun;69(6):1736-1746. (PMID: 30591300)
Br J Surg. 2013 Sep;100(10):1397-8. (PMID: 23939855)
J Vasc Surg. 2016 Jan;63(1):32-8. (PMID: 26432285)
Interact Cardiovasc Thorac Surg. 2010 Jul;11(1):78-82. (PMID: 20378698)
BMJ. 2010 Mar 23;340:c332. (PMID: 20332509)
J Ultrasound. 2019 Mar;22(1):65-75. (PMID: 30771104)
Eur J Vasc Endovasc Surg. 2016 May;51(5):632-9. (PMID: 26860254)
J Endovasc Ther. 2021 Apr;28(2):332-341. (PMID: 33236681)
Ann Vasc Surg. 2018 Jul;50:195-201. (PMID: 29501597)
Br J Surg. 2008 Jun;95(6):677-84. (PMID: 18446774)
Eur J Vasc Endovasc Surg. 2019 Jan;57(1):8-93. (PMID: 30528142)
J Ultrasound. 2015 Jan 17;18(2):91-9. (PMID: 26191109)
J Vasc Surg. 2019 Oct;70(4):1318-1326.e5. (PMID: 30792063)
J Vasc Surg. 2013 Apr;57(4):934-41. (PMID: 23384494)
Clin Epidemiol. 2020 Jan 23;12:95-103. (PMID: 32158272)
Glob Heart. 2014 Mar;9(1):159-70. (PMID: 25432125)
Cochrane Database Syst Rev. 2014 Jan 23;(1):CD004178. (PMID: 24453068)
Eur J Vasc Endovasc Surg. 2021 Feb;61(2):201-209. (PMID: 33342658)
J Vasc Surg. 2010 Jul;52(1):19-24. (PMID: 20478685)
- Grant Information:
01KG2128 Bundesministerium für Bildung und Forschung
- Contributed Indexing:
Keywords: Aortic aneurysm; Embolization; Endoleak; Endovascular; Prevention; Prospective studies
- Molecular Sequence:
ClinicalTrials.gov NCT05665101
- الموضوع:
Date Created: 20240103 Date Completed: 20240105 Latest Revision: 20240106
- الموضوع:
20240106
- الرقم المعرف:
PMC10759747
- الرقم المعرف:
10.1186/s13063-023-07888-8
- الرقم المعرف:
38167068
No Comments.